Cost Effectiveness [qnco]
exemestane [phsu, strd]
Tamoxifen [orch, phsu]
adjuvant therapy [topp]
early-stage breast cancer [neop]
treatment [ftcn]
Tamoxifen [orch, phsu]
Sweden [geoa]
Aromatase Inhibitors [phsu]
Rapidly [qlco]
Endocrine [bdsy]
treatment [ftcn]
Advanced [qlco]
Disease [dsyn]
Now [tmco]
Adjuvant [chvf]
treatment [ftcn]
early disease [tmco]
Stage [tmco]
Objective [inpr]
Study [mnob]
To [qlco]
Assess [acty]
Cost Effectiveness [qnco]
Adjuvant [chvf]
treatment [ftcn]
exemestane [phsu, strd]
Tamoxifen [orch, phsu]
early-stage breast cancer [neop]
treatment [ftcn]
Tamoxifen [orch, phsu]
Sweden [geoa]
Result [ftcn]
Based [ftcn]
findings [ftcn]
exemestane [phsu, strd]
Study [mnob]
exemestane [phsu, strd]
Study [mnob]
randomized controlled trial [inpr, resa]
postmenopausal [tmco]
Women [popg]
Received [qlco]
Tamoxifen [orch, phsu]
therapy [ftcn]
Following [tmco]
primary treatment [topp]
early-stage breast cancer [neop]
randomized [resa]
Continue [idcn]
Tamoxifen [orch, phsu]
therapy [ftcn]
Switch [mnob]
exemestane [phsu, strd]
therapy [ftcn]
Result [ftcn]
Show [inpr]
Disease-Free Survival [qnco]
Hazard Ratio [qnco]
exemestane [phsu, strd]
Relative [famg]
Tamoxifen [orch, phsu]
exemestane [phsu, strd]
Study [mnob]
State transition [idcn]
Model [inpr]
To [qlco]
simulate [bodm]
consequences [ftcn]
End [spco]
Clinical Trial [resa]
To [qlco]
Trial [resa]
Data [idcn]
External [spco]
Data [idcn]
Mortality [qnco]
Costs [qnco]
Quality [qlco]
Life [idcn]
Specific [qlco]
Swedish [popg]
Women [popg]
Cost [qnco]
QALY [tmco]
Gain [qnco]
base [inch]
Case [ftcn]
Analysis [lbpr]
Inclusion [qlco]
consequences [ftcn]
coronary heart disease [dsyn]
Inclusion [qlco]
Events [evnt]
Increased [qnco]
Cost Effectiveness [qnco]
Ratio [qnco]
This [euka]
Means [cnce]
Based [ftcn]
Sequential Treatment [topp]
exemestane [phsu, strd]
Early [tmco]
Breast Cancer [neop]
Cost Effectiveness [qnco]
Option [ftcn]
Compared [acty]
Tamoxifen [orch, phsu]
Alone [qnco]
More [ftcn]
Long-term [tmco]
Data [idcn]
Overall [inpr]
Survival [acty]
consequences [ftcn]
adverse events [fndg]
Increase [ftcn]
Validity [qnco]
Analysis [lbpr]
Further [spco]
